mProX™ Human JAK2 Stable Cell Line

Product Information

Target Protein

JAK2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

Ba/F3; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Related Diseases

Polycythemia Vera and Thrombocythemia 3. Among its related pathways are Signaling downstream of RAS mutants and Prolactin Signaling

Gene ID

3717

UniProt ID

O60674

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The JAK2 gene provides instructions for making a protein that promotes the growth and division of cells. This protein is part of a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus. The JAK2 protein is especially important for controlling the production of blood cells from hematopoietic stem cells. These stem cells are located within the bone marrow and have the potential to develop into red blood cells, white blood cells, and platelets. The customized JAK2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Jessica

This is a very reliable human JAK2 cell line with high sensitivity and specificity. Mar 19 2022

chat Verified Customer

chat Kathleen

Recommended for all labs based on my experience of using this JAK2 cell line. Jan 27 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 JAK2 mutant Ba/F3-MPL cell line generation.

Quantification of human JAK2 cDNA levels was done, and no discernible variation was seen between the four cell lines when the levels were normalized using endogenous mouse Jak2 cDNA levels. Western blot analysis was used to determine that all 4 cell lines had similar levels of total JAK2 and MPL protein.

Ref: Etheridge, S. Leah, et al. "A novel activating, germline JAK2 mutation, JAK2 R564Q, causes familial essential thrombocytosis." Blood, The Journal of the American Society of Hematology 123.7 (2014): 1059-1068.

Pubmed: 24381227

DOI: 10.1182/blood-2012-12-473777

Research Highlights

Although the crucial function of Janus kinase-2 (JAK2) in controlling myelopoiesis was recognized twenty years ago, JAK2's involvement in human illness was brought to light by the discovery of mutations in the pseudokinase domain of JAK2 in myeloproliferative neoplasms (MPNs) and other hematologic malignancies.
Silvennoinen, Olli, and Stevan R. Hubbard. "Molecular insights into regulation of JAK2 in myeloproliferative neoplasms." Blood, The Journal of the American Society of Hematology 125.22 (2015): 3388-3392.
Pubmed: 25824690 DOI: 10.1182/blood-2015-01-621110

These findings imply that when treating JAK2-amplified TNBCs, JAK2-specific inhibitors are more effective than dual JAK1/2 inhibitors. Moreover, JAK2 amplification may serve as a biomarker for JAK2 dependence, which may be utilized to identify individuals for JAK2 inhibitor clinical trials.
Balko, Justin M., et al. "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence." Science translational medicine 8.334 (2016): 334ra53-334ra53.
Pubmed: 27075627 DOI: 10.1126/scitranslmed.aad3001